Introduction
============

Focal segmental glomerulosclerosis (FSGS) is one of the most common causes of proteinuric kidney disease that eventually progresses to the end-stage renal failure. Molecular studies revealed a central role of glomerular podocyte damage in the development of FSGS.[@b1-ccrep-9-2016-015],[@b2-ccrep-9-2016-015] A growing number of proteins, expressed by podocytes, contributing to the structure and function of the slit diaphragm (eg, nephrin (*NPHS1*), podocin (*NPHS1*)), cytoskeleton (eg, alpha-actinin 4 (*ACTN4*)) and/or podocyte signaling (eg, inverted formin 2 (*INF2*), Wilms tumor protein 1 (*WT1*), TRPC6 (*TRPC6*), PLCE1 (phospholipase C epsilon 1, *PLCE1*)), cause FSGS when mutated.[@b1-ccrep-9-2016-015],[@b2-ccrep-9-2016-015]

The lack of CD2-associated protein (CD2AP) in mice results in severe congenital nephrotic syndrome: *Cd2ap*^−/−^ mice die of massive proteinuria shortly after birth, and *Cd2ap*^+/−^ mice present glomerular disease at nine months with a kidney histology that mimics human FSGS.[@b3-ccrep-9-2016-015] The renal phenotype of *Cd2ap*^−/−^-deficient animals is rescued by podocyte transfection with CD2AP.[@b4-ccrep-9-2016-015]

In spite of the clear association of CD2AP defects with a glomerular pathology reminiscent of FSGS in mouse models, little is known about CD2AP in humans. Kim et al described one heterozygous nucleotide variant resulting in an aberrant *CD2AP* splicing in two patients with idiopathic FSGS.[@b3-ccrep-9-2016-015] The protein product of this variant message would lack \>80% of the CD2AP protein. Löwik et al described a patient affected by early onset nephrotic syndrome with a *CD2AP* homozygous mutation (p.R612X), resulting in a premature stop codon yielding a slightly truncated protein (by only 4%).[@b5-ccrep-9-2016-015] The boy was born of consanguineous parents of Mediterranean ancestry, each of whom was unaffected and carried the mutation in heterozygous state, indicating that heterozygosity for this mutation does not result in kidney disease. Three additional heterozygous mutations in *CD2AP* (p.K301M, p.T374A, p.delGlu525) were found in three unrelated Italian patients with idiopathic FSGS.[@b6-ccrep-9-2016-015] Two recently identified mutations in *CD2AP* (IVS13-137G \> A, IVS7--135G \> A) are likely FSGS-causing DNA variants.[@b7-ccrep-9-2016-015]

Overall, the mutations described so far remain unique, so it is still uncertain whether *CD2AP* mutations have a real clinical impact in causing an inherited form of FSGS in man. In this study, we report a German patient with steroid-resistant FSGS and identified a heterozygous *CD2AP* mutation (p.T374A), which was previously identified in an unrelated Italian patient with FSGS.[@b6-ccrep-9-2016-015] Our results show that a unique heterozygous *CD2AP* mutation (p.T374A) occurs independently in two different patients/families with FSGS, supporting the idea that p.T374A is likely a pathogenic mutation and the overall concept that *CD2AP*-associated nephropathy is an autosomal dominant form of FSGS in man. The patient has given consent for publication of this report.

Case Presentation
=================

The 32-year-old patient presented with a nephrotic syndrome (proteinuria \>3.5 g/day) at the age of 28. He had swellings around his eyes, swollen ankles and feet, and foamy urine. There was no remarkably deteriorated kidney function at the point of initial presentation (serum creatinine, 110 μmol/L; estimated glomerular filtration rate (eGFR) 77.7 mL/minute). He is the child of nonconsanguineous German parents. He successfully completed 10 years of middle school education and a three-year apprenticeship (Berufsschule) as a carpenter. The patient reported that his mother and his only brother also have a kidney disease. Otherwise, his family history is not remarkable. Blood samples or clinical reports of his relatives are not available because he lost all contacts with them. Never theless, the family history is consistent with an autosomal dominant pattern of the disease.

Kidney biopsy showed the histopathological findings of FSGS ([Figs. 1A](#f1-ccrep-9-2016-015){ref-type="fig"} and [1B](#f1-ccrep-9-2016-015){ref-type="fig"}; [Supplementary Fig. 1](#s1-CCRep-9-2016-015){ref-type="supplementary-material"}). Therapy with steroids was performed over a six-month period with a transient clinical benefit. Concomitantly, the patient received anti-proteinuric therapy with an angiotensin-converting enzyme inhibitor (ramipril, 10 mg/day). Because of the relapse of proteinuria (\>3.5 g/day), he received a repeated kidney biopsy, which also confirmed FSGS. Neurological examination showed a remarkable cognitive decline within five years of his initial presentation. Interestingly, one physician initially suspected an alcoholic etiology of the cognitive impairment in our patient, but a more detailed examination of the patient's behavior and social environment by his local nephrologists, neurologist, and assisted living staff revealed this etiology to be rather unlikely. After five years of initial presentation, the patient's mini--mental state examination score was 21 out of 30.

Mutational analysis revealed a heterozygote p.T374A, c.1120 A \> G mutation in *CD2AP* ([Fig. 2A](#f2-ccrep-9-2016-015){ref-type="fig"}). The mutation is located in the coding region of the proline-rich domain of CD2AP ([Fig. 2B](#f2-ccrep-9-2016-015){ref-type="fig"}). The same mutation was previously identified in a patient with histology-proven FSGS, who developed nephrotic syndrome at early childhood similar to other patients with *CD2AP*-associated nephropathy ([Table 1](#t1-ccrep-9-2016-015){ref-type="table"}).[@b6-ccrep-9-2016-015] We did not find mutations in other known FSGS genes causing autosomal dominant FSGS, including *TRPC6*, *ACTN4*, and *WT1* (*NPHS4*; exons 8 und 9). In *INF2*, we found a small deletion (6 bp) in exon 8, which results in a deletion of two amino acids (p.PPL \> L (427--429)). Small deletions in this gene region are reported in NHLBI Exome Sequencing Project Exome Variant Server TMP_ESP_14_105173884, but not in Human Genome Mutation Database (HGMD Pro; [www.hgmd.cf.ac.uk](http://www.hgmd.cf.ac.uk)) or Ensembl ([www.ensembl.org](http://www.ensembl.org)). The significance of this deletion is unknown but is not predicted to be pathogenic by SIFT[@b8-ccrep-9-2016-015] and MutationTaster[@b9-ccrep-9-2016-015] predictions algorithms.

Subsequently, a therapy with steroid (prednisolone, 5 mg/day) and low-intermediate doses of cyclosporine A (CsA; trough levels, 15--30 μg/L) was performed. This therapy led to a persistent reduction of proteinuria. Serum creatinine levels and eGFR reached a plateau and did not decline during this treatment ([Fig. 3](#f3-ccrep-9-2016-015){ref-type="fig"}).

Methods
=======

The patient was entered into genetic testing after having given written informed consent. DNA was isolated from peripheral blood leukocytes, using a commercially available DNA isolation kit: EZ1 DNA Blood 200-μL Kit, QIAGEN EZ1 DNA Blood card, as suggested by Qiagen Supplementary Protocol. The amplification of *TRPC6* (GenBank accession number, Ensembl Transcript ID ENST00000344327), *ACTN4* (ENST00000252699), *WT1* (ENST00000332351), *CD2AP* (ENST00000359314), and *INF2* (ENST00000392634) exons was performed by the polymerase chain reaction (PCR). Primer data and PCR protocols are available on request. The 5′-UTR of *CD2AP* was also analyzed. The PCR products were analyzed with ABI 3100-Avant Genetic Analyzer (Applied Biosystems) by BigDye terminator reaction according to the supplier's instructions (ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kits Version 1.1; Applied Biosystems). The sequences were analyzed by Sequence Pilot program with the SeqPatient V.3.5.2 module (JSI medical system GmbH). Paraffin sections from kidney biopsy were analyzed by routine renal biopsy examination.

Conclusion
==========

Mutations in CD2-associated protein gene (*CD2AP*) have been identified in patients with FSGS ([Table 1](#t1-ccrep-9-2016-015){ref-type="table"}). However, reports of *CD2AP* mutations and the associated phenotype(s) remain scarce. All previous reports describe the sequence variations/mutations of *CD2AP* in individuals of unrelated families. However, there are no reports on unrelated patients who have any of these known mutations and FSGS. In addition, there is no proven effective therapy for *CD2AP*-associated nephropathy.

Ours is the first case of *CD2AP*-associated nephropathy associated with a sequence variation (p.T374A, c.1120 A \> G), which was previously reported for another, unrelated patient with this disorder.[@b6-ccrep-9-2016-015] Of note in the study by Gigante et al, the patient presented overt proteinuria with nephrotic syndrome at pediatric age. As known for other cases of *CD2AP*-associated nephropathy,[@b5-ccrep-9-2016-015],[@b6-ccrep-9-2016-015],[@b10-ccrep-9-2016-015] his nephropathy showed a high degree of resistance to steroids, but definitive data on progression to end-stage renal failure are not available. Clinical data of his family members were not available to determine cosegration of this mutation with the phenotype.[@b6-ccrep-9-2016-015] In contrast to the patient in Gigante et al, our patient developed overt proteinuria at the adult age ([Table 1](#t1-ccrep-9-2016-015){ref-type="table"}). The kidney biopsies in both patients showed FSGS. In addition, proteinuria in both patients was resistant to steroids. Accordingly, the p.T374A mutation is now the first sequence variation of *CD2AP* found in two unrelated patients/families with FSGS, which consolidates the idea that this mutation is a likely pathogenic mutation causing FSGS in humans.[@b11-ccrep-9-2016-015] Moreover, our findings support the concept that haploinsufficiency in *CD2AP* can cause FSGS in humans. In the 1000 genomes browser, the p.T374A is reported in \<0.5% of population, but clinical data are missing. The mutation (c.1120 A \> G) produces an A-to-G nucleotide change in exon 12, resulting in the substitution of threonine 374 with alanine (p.T374A).[@b6-ccrep-9-2016-015] It is a missense mutation localized in the proline-rich domain containing three core PXKP motifs that act as binding sites for the SH3 domain of other podocyte proteins. Multiple alignments of amino acid sequences showed high conservation of Thr-374 across animal species.[@b6-ccrep-9-2016-015] Together, the present data support the view that *CD2AP* p.T374A is likely a FSGS-causing mutation in humans.

Our patient is the first patient with *CD2AP*-associated nephropathy treated with low-dose steroids and low-intermediate doses of CsA. This treatment reduced his proteinuria rate by \~70%. Although definitive data on the progression to advanced stage renal failure are not available, this reduction in proteinuria is remarkable. We believe that our report may be useful for nephrologists who treat patients with *CD2AP*-associated nephropathy. Our data indicate that CsA is a therapeutic option for patients with *CD2AP*-associated nephropathy. On the other hand, the CsA response may explain why only very few patients with *CD2AP*-associated nephropathy have been identified so far.[@b12-ccrep-9-2016-015] Genetic testing is usually performed in patients with kidney disease who are distinct from these clinical features, namely patients with therapy-resistant FSGS and a positive family history. Interestingly, *MYO1E*- and *PLCE1*-associated nephropathies are the only hereditary kidney diseases known to respond to treatment with CsA.[@b13-ccrep-9-2016-015],[@b14-ccrep-9-2016-015] The mechanism is unknown, but there is evidence that CsA may exhibit protective effects in podocytes by blocking synaptopodin dephosphorylation[@b15-ccrep-9-2016-015] and the loss of CD2AP.[@b16-ccrep-9-2016-015]

Our patient displayed mild dementia in young adulthood, a phenotypic characteristic not previously associated with *CD2AP*-associated FSGS. It is not clear whether this feature represents a typical characteristic of those patients in adulthood or not. The majority of patients with *CD2AP*-associated nephropathy had onset of renal symptoms before five years of age ([Table 1](#t1-ccrep-9-2016-015){ref-type="table"}), and there is no information about their intellectual capabilities at an adult age. It is important to know whether cognitive impairment will also develop in patients with childhood-onset, *CD2AP*-associated nephropathy later in life. Of note, common variants at *CD2AP* are associated with Alzheimer's disease,[@b17-ccrep-9-2016-015] which may indicate that *CD2AP* mutations can be associated with or cause cognitive impairment. Nevertheless, we cannot rule out with absolute certainty that other factors could have caused or contributed to our patient's mild dementia.

In conclusion, our findings expand the clinical spectrum of *CD2AP*-associated disorders. The results highlight the impact of *CD2AP* mutations also in adulthood proteinuric disease. From the clinical point of view, the genetic testing of *CD2AP* should be considered in adulthood steroid-resistant nephrotic syndrome/FSGS. Our case shows that cyclosporin A is a treatment option for FSGS in p.T374A *CD2AP*-associated nephropathy.

Supplementary Material
======================

###### 

**Supplementary Figure 1**. Arrow A shows a glomerulus with normal capillary loops, regular thickness of mesangial matrix and peripheral capillary basement membrane, and flat podocytes. Arrow B shows a glomerulus with segmental glomerular sclerosis. This glomerulus shows the loss of capillary lumen and the adhesion of sclerotic lesions to the Bowman's capsule. No mesangial and endothelial hypercellularity, no activated podocytes. Chronic unspecific inflammation accompanying with interstitial fibrosis and tubular atrophy (PAS × 200).
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![Histopathological findings of a kidney biopsy of our patient. (**A**) Electron microscopy showing peripheral glomerular loop with widespread podocyte foot processes effacement (arrows). Mesangium, endothelium, and glomerular basement membrane are normal. Scale bar = 2 μm. (**B**) Light microscopy showing a glomerulus with segmental glomerular sclerosis. This glomerulus shows the loss of capillary lumen and the adhesion of sclerotic lesions to the Bowman's capsule. No endothelial hypercellularity and no activated podocytes. Scale bar = 50 μm.](ccrep-9-2016-015f1){#f1-ccrep-9-2016-015}

![(**A**) DNA-sequencing fluorograms demonstrating heterozygosity for c.1120 A \< G in *CD2AP* in our patient. (**B**) Schematic representation of the CD2AP protein. Mutation positions are indicated by arrows. SH3, SH3 domains; PRD, proline-rich domain. Coiled-coil domain located at the C terminus.](ccrep-9-2016-015f2){#f2-ccrep-9-2016-015}

![Treatment of our patient with CsA. (**A**) Decline of proteinuria measured in grams per day or as protein/creatinine ratio (g/g) in urine samples during the treatment of the patient with CsA. (**B**) Serum creatinine and eGFR (CKD-Epi) measured during the treatment of the patient with CsA.](ccrep-9-2016-015f3){#f3-ccrep-9-2016-015}

###### 

Described cases of focal segmental glomerulosclerosis with mutations in *CD2AP.*

  PATIENT ID                                              SEX                                                     NUCLEOTIDE CHANGE; AA CHANGE    AGE AT ONSET (YEARS)                                     RESISTANCE TO STEROIDS                                       REF.
  ------------------------------------------------------- ------------------------------------------------------- ------------------------------- -------------------------------------------------------- ------------------------------------------------------------ -------------------------------
  1, 2[\#](#tfn1-ccrep-9-2016-015){ref-type="table-fn"}   F, M[\#](#tfn1-ccrep-9-2016-015){ref-type="table-fn"}   c.1120 A \> G; p.T374A het      2, 28[\#](#tfn1-ccrep-9-2016-015){ref-type="table-fn"}   Resistant[\#](#tfn1-ccrep-9-2016-015){ref-type="table-fn"}   Gigante[@b6-ccrep-9-2016-015]
  3                                                       F                                                       c.904 A \> T; p.K301M het       23                                                       Resistant                                                    Gigante[@b6-ccrep-9-2016-015]
  4                                                       M                                                       c.1573delAGA; p.delGlu525 het   2                                                        Resistant                                                    Gigante[@b6-ccrep-9-2016-015]
  5                                                       M                                                       c.1834 C \> A; R612X hom        1                                                        Resistant                                                    Löwik[@b5-ccrep-9-2016-015]
  6                                                       M                                                       c.1488 G \> A; p.M496I het      3.5                                                      Resistant                                                    Löwik[@b10-ccrep-9-2016-015]
  7                                                       M                                                       IVS13-137G \> A het             8                                                        Resistant                                                    Feng[@b7-ccrep-9-2016-015]
  8                                                       M                                                       IVS7-135G \> A het              4.7                                                      Resistant                                                    Feng[@b7-ccrep-9-2016-015]

**Note:**

Our index patient.

**Abbreviations:** M, male; F, female; AA, amino acid; het, heterozygous; hom, homozygous.
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